Primary immunosuppressive TNI-based conditioning regimens in pediatric patients treated with haploidentical

D Wegener1, P Lang2, F Paulsen3

  • 1Department of Radiation Oncology, University Clinic of Tuebingen, Tuebingen, Germany. Daniel.Wegener@med.uni-tuebingen.de.

Insights

A modified total nodal irradiation (TNI) conditioning regimen before haploidentical hematopoietic cell transplantation (HCT) in children showed good engraftment and long-term survival. Late toxicities were manageable, including growth issues and hormonal deficiencies.

Area of Science:

  • Pediatric Hematology
  • Oncology
  • Radiation Oncology

Background:

  • Haploidentical hematopoietic cell transplantation (HCT) offers an alternative for patients lacking matched donors.
  • Total nodal irradiation (TNI) is a conditioning regimen used prior to HCT.
  • Optimizing TNI regimens for pediatric HCT is crucial for improving outcomes.

Purpose of the Study:

  • To evaluate the toxicity and efficacy of a modified total nodal irradiation (TNI)-based conditioning regimen.
  • To assess outcomes in pediatric patients undergoing haploidentical HCT with this regimen.

Main Methods:

  • Retrospective analysis of 7 pediatric patients (2 malignant, 5 non-malignant diseases).
  • Patients received a single-dose 7 Gy TNI regimen with systemic agents before haploidentical HCT.
  • Long-term follow-up data was collected and analyzed.

Main Results:

  • Successful engraftment in 6/7 patients; one required reconditioning.
  • Event-free survival (EFS) of 71.4% and overall survival (OS) of 85.7% after a median follow-up of 103.5 months.
  • Late toxicities included manageable hormonal deficiencies (3/5), growth failure (2/5 height, 1/5 weight), and acceptable lung function decline (FEV1 71%, VC 78%). No secondary malignancies were reported.

Conclusions:

  • A single-dose 7 Gy TNI-based conditioning regimen is effective for pediatric haploidentical HCT.
  • The regimen supports sustained engraftment and long-term survival with a tolerable toxicity profile.
  • Late toxicities are manageable, supporting the use of this regimen in pediatric HCT.
Abstract